Chemistry:AEE788
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H32N6 |
| Molar mass | 440.595 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
AEE788 is a multitargeted human epidermal receptor (HER) 1/2 and vascular endothelial growth factor receptor (VEGFR) 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1.[1] In cells, growth factor-induced EGFR and ErbB2 phosphorylation was also efficiently inhibited with IC50s of 11 and 220 nM, respectively. It efficiently inhibited growth factor-induced EGFR and ErbB2 phosphorylation in tumors for >72 h, a phenomenon correlating with the antitumor efficacy of intermittent treatment schedules. It also inhibits VEGF-induced angiogenesis in a murine implant model. It has potential as an anticancer agent targeting deregulated tumor cell proliferation as well as angiogenic parameters.[2][3]
The IC50 value of AEE788 against of different kinases
| Kinase | IC50(nM) |
|---|---|
| EGFR ICD | 2 |
| ErbB2(HER-2) | 6 |
| ErbB4 (HER-4) | 160 |
| KDR | 77 |
| Tek | 2100 |
| IGF1-R | >10000 |
| Ins-R | >10000 |
| PDGFR-beta | 320 |
| c-Met | 2900 |
| c-Abl | 52 |
| c-Src | 61 |
| c-Kit | 790 |
| RET | 740 |
| c-Fms | 60 |
| Flt-1 | 59 |
| Flt-3 | 730 |
| Flt-4 | 330 |
| Cdk1/Cyc.B | 8000 |
| PKC-alpha | >10000 |
| c-Raf-1 | 2800 |
| PKA | >10000 |
The data of antiproliferative activity of AEE788
| Cell line | IC50(nM) |
|---|---|
| NCI-H596 | 78 |
| MK | 56 |
| BT-474 | 49 |
| SK-BR-3 | 381 |
| 32D/EGFR | 300 |
| 32D/EGFRvIII | 10 |
| MCF-7 | 2500 |
| MCF-7/EGFRvIII | <5000 |
| T24 | 4526 |
References
- ↑ "AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity". Cancer Res. 64 (14): 4931–41. Jul 2004. doi:10.1158/0008-5472.CAN-03-3681. PMID 15256466.
- ↑ "Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells". BMC Cancer 9 (161): 161. May 2009. doi:10.1186/1471-2407-9-161. PMID 19473483.
- ↑ "Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of Medulloblastoma.". Transl Oncol. 3 (5): 326–35. Oct 2010. doi:10.1593/tlo.10163. PMID 20885895.
